The TAC universe grows beyond PROTACs
Inducing autophagy is becoming a popular strategy as targeting chimeras extend beyond protein degradation
On the heels of success using the proteasome to degrade protein targets, a growing crop of companies are turning to autophagy to destroy a broader array of disease-driving substrates.
The TAC (therapeutic targeting chimera) space took off with modular compounds known as proteolysis targeting chimeras (PROTACs), which ubiquitinate targets and send them to the proteasome for degradation...
BCIQ Company Profiles
Broad Institute of MIT and Harvard